


RealRate

PHARMACEUTICAL 2017

GT Biopharma Inc. Rank 1 of 313







RealRate

PHARMACEUTICAL 2017

GT Biopharma Inc. Rank 1 of 313

The relative strengths and weaknesses of GT Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GT Biopharma Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 1,698% points. The greatest weakness of GT Biopharma Inc. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 1,215% points.

The company's Economic Capital Ratio, given in the ranking table, is 681%, being 1,097% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	21
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	18,949
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	30,407
Property and Equipment	4.0
Research and Development	975
Revenues	0
Selling, General and Administrative Expense	8,399

Output Variable	Value in 1000 USD
Assets	25
Liabilities	18,949
Expenses	9,374
Stockholders Equity	-18,924
Net Income	21,033
Comprehensive Net Income	21,033
Economic Capital Ratio	681%

